Several GLS inhibitors have been developed, among which CB-839 is currently undergoing clinical trials as a potent, orally bioavailable GLS-selective inhibitor for the treatment of various cancers, including TNBC, NSCLC, and colon cancer (NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600)
This stepped approach saves money upfront while preserving tirzepatide as an escalation option
Mechanism of Interest L-Carnitine is of interest for its role in shuttling long-chain fatty acids into mitochondria, enabling research into metabolic transport systems
You can train hard and stay disciplined with your nutrition, yet sometimes progress slows down or becomes frustratingly inconsistent
11-4E) Treatment of psoriatic nail changes of the feet is generally unsatisfactory